American Society of Hematology's 2012 Annual Meeting

The Hope for Personalized Medicine in Myeloma

Dr. Mario Boccadoro shares his perspective on the improving prospects for patients with the disease and comments on efforts to personalize treatment for each patient.

Published:

An Advocate's Perspective on the Latest Developments in Myeloma

Susie Novis, co-founder of the International Myeloma Foundation, joins Andrew at the 2012 ASH meeting to share her perspective on news being presented for patients.

Published:

Published:

Effective Therapies for Myeloma Patients After Disease Relapse

Dr. William Bensinger, myeloma expert from the Seattle Cancer Care Alliance, discusses research results that offer hope for patients who experience disease relapse after an allogeneic stem cell transplant.

Published:

Research Efforts Focus on Increasing Treatment Response for Multiple Myeloma Patients

Dr. William Bensinger shares results from a study reported at ASH 2012 using an older drug, amifostine, in a new way; protecting patients from toxicity while patients receive higher and more effective doses of cancer-fighting drugs.

Published:

Published:

Published:

Published:

Published:

Published:

Published:

Published:

Published:

Published:

Big Changes in CLL Treatment Mean Opportunities for Patients

Dr. John Pagel details important advances that signal a changing treatment landscape in CLL with new options for patients, with updates from ASH 2012

Published:

Published:

Published:

Published:

Published:

An Expert’s Perspective on Changing CML Treatment Options

Dr. Moshe Talpaz discusses when the "big guns"of treatment should be used and how there are now treatment options that address certain resistant mutations including the T315I.

Published:

A CML Advocate's Perspective on News from ASH 2012

Executive Director of the National CML Society, Greg Stephens, gives his perspective on news for CML patients from the 2012 ASH Meeting.

Published:

Published:

New, Longer Term Research Shows Myelofibrosis Drug to be More Effective, Appears to Extend Survival

New updated research results on Jakafi (ruxolitinib) show positive news to prove to be more effective than hydroxyurea for the treatment of myelofibrosis, according to a new study released at ASH 2012.

Published:

Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations

Dr. Ruben Mesa of the Mayo Clinic, shares his optimism for patients living with myeloproliferative disorders, particularly Myelofibrosis.

Published:

El experto opina: las últimas noticias sobre las Neoplasias Mieloproliferativas (MPN) tras concluir la convención de la Sociedad Americana de Hematología, ASH 2012

El tratamiento de las MPN tiene buenas perspectivas; el Dr. Ruben Mesa nos da su opinión tras asistir a la convención ASH.

Published:

Published:

Published:

How Doctors Are Improving Myeloma Outcomes with Personalized Medicine

Personalized medicine is the future of myeloma treatment. Dr. Shaji Kumar discusses how the variety of therapies and better understanding of genetic components are coming together to achieve better outcomes.

Published:

A New Backbone Therapy in the Future for Myeloma Treatment

Research is showing that proteasome inhibitors are incredibly effective at treating many stages of myeloma. Dr. Shaji Kumar talks about how this therapy is becoming a new backbone treatment for myeloma.

Published:

How Doctors Decide Treatments for Newly Diagnosed Myeloma Patients

We're learning a lot about choosing the right treatment plan for each patient. Drs. Shaji Kumar and Noopur Raje talk about what information helps them decide the right plan for each patient.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 4, 2014